Opus Genetics reports that the first participant in its phase 1/2 trial of OPGx-RDH12 has received the investigational gene therapy. The study is testing the treatment in people with RDH12-associated Leber congenital amaurosis, an inherited retinal disease that causes progressive vision loss beginning in early childhood. The company estimates that the disease affects about 2,500 people in the United States.
OPGx-RDH12 is designed to deliver a functional copy of the RDH12 gene to retinal photoreceptors. The trial will assess safety and tolerability and examine retinal structure and visual function as exploratory measures.
The US Food and Drug Administration cleared the company’s investigational new drug application in October. OPGx-RDH12 is the third Opus Genetics gene therapy to enter clinical testing.
The Global RDH12 Alliance, which brings together RDH12 Fund for Sight in the United States and Eyes on the Future in the United Kingdom, has committed up to $1.6 million toward development. The agreement ties reimbursement of eligible costs to completed work and specified milestones. RP







